EOS imaging Announces Second Installation at Hospital for Special Surgery in New York City

EOS Imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging and associated solutions, today announced the second EOS imaging system installation at New York City’s Hospital for Special Surgery (HSS). This second installation at HSS brings EOS’ installed base in Manhattan to five, with a sixth unit shipped and pending installation.

Hospital for Special Surgery is an international leader in orthopedic surgery and rheumatology, performing more than 26,000 surgeries last year. It has been named the number one hospital in the U.S. for orthopedics by U.S. News & World Report for three years in a row.

"We have been happy EOS users since early 2013, when we installed our first system for pediatric patients at the Lerner Children’s Pavilion. Adoption was so complete, in fact, that other surgeons in the hospital seeing adult patients for hip and knee surgeries started using the EOS for surgical planning as well. This new installation, in the 3rd Floor Radiology Department, will be beneficial to our practice and to our patients and will service our Adult population,” said Edward White, Assistant Vice-President for the Department of Radiology and Imaging at HSS.

Marie Meynadier, CEO of EOS imaging, said, "As the national leader for orthopedic surgery in the U.S., HSS was attracted to the prospect of having the most cutting-edge imaging technology to offer patients – especially pediatric patients with conditions like scoliosis that require regular monitoring. The growing demand of adult surgeons for exams leading to this installation speaks for the value of our imaging platform and associated software solutions in hip and knee arthroplasty. We are proud to be a continued partner of the nation’s best orthopedic surgery hospital.”

The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans, as well as related software solutions. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3^rd quarter of 2015, on October 20, 2015 (after market).

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled Georges Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and Singapore.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150909006616/en/